Researchers at Imperial College London are integrating the PrecivityAD2 blood test from C2N Diagnostics into primary care pathways to accelerate Alzheimer’s disease diagnoses, according to a university release. Launched in May as part of the Davos Alzheimer’s Collaborative Healthcare System Preparedness program, the BEAD-PC study evaluates patients aged 50 and older showing signs of mild cognitive impairment or dementia.
Clinical Integration in Primary Care Settings
General practitioners in North West London are using the blood-based biomarker test alongside standard cognitive assessments within routine appointments, according to study protocols. The PrecivityAD2 assay is specifically designed to detect amyloid plaques in the brain, offering sensitivity and specificity comparable to specialized imaging and cerebrospinal fluid tests, according to Lefkos Middleton, professor of neurology at Imperial.
When results indicate early-stage cognitive impairment, clinicians refer patients to the Imperial Memory Unit at Charing Cross Hospital for specialist evaluation. This framework shifts diagnostic capabilities directly into primary care sites to bypass typical delays associated with hospital-only evaluations.
Pro Tip: Blood-based biomarkers help bridge the gap between initial patient concerns and formal specialist referrals by providing measurable indicators of brain pathology during early clinical visits.
Addressing the Diagnostic Gap in Dementia Care
The Davos Alzheimer’s Collaborative initiative generates real-world evidence to inform potential scale-up across the National Health Service and other healthcare systems. Historically, clinicians have operated in a grey area when assessing patient memory concerns without precise biological tools, according to David Wingfield, professor of practice at Imperial.
By identifying amyloid pathology earlier through accessible blood draws, healthcare providers can better define the underlying disease process and connect patients with appropriate clinical trials or emerging treatments sooner.
Did You Know? The BEAD-PC study at Imperial College London is currently the only center in the United Kingdom participating in this specific Davos Alzheimer’s Collaborative preparedness program.
Frequently Asked Questions
What is the PrecivityAD2 test?
The PrecivityAD2 test is a blood-based biomarker assay produced by C2N Diagnostics that detects amyloid plaques in the brain for patients aged 50 and older exhibiting signs of cognitive impairment.
How does the BEAD-PC study work?
General practitioners in North West London administer the blood test during routine appointments alongside standard cognitive assessments, referring patients with positive indicators to the Imperial Memory Unit at Charing Cross Hospital.
Who is leading this research initiative in the United Kingdom?
Imperial College London launched the study in partnership with the Davos Alzheimer’s Collaborative, involving faculty members including Lefkos Middleton and David Wingfield.
Want to stay updated on the latest clinical advancements in neurology and healthcare delivery? Subscribe to our newsletter for regular updates, or explore our medical research archive for more in-depth reporting.
Keep reading